斯托克治疗公司(LENZ) (NASDAQ:STOK)报告称季度每股亏损为$(0.18)，好于分析师一致预期的$(0.53)，提高了66.04%。相比去年同期每股亏损$(0.60)，这是70%的增长。公司报告季度销售额为$22.60百万，远高于分析师一致预期的$4.28百万，增幅为428.04%。相比去年同期的$2.80百万，这一销售额增长了706.85%。

以上内容来自Benzinga Earnings专栏，原文如下：

Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.53) by 66.04 percent. This is a 70 percent increase over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $22.60 million which beat the analyst consensus estimate of $4.28 million by 428.04 percent. This is a 706.85 percent increase over sales of $2.80 million the same period last year.